Group 1: Company Overview and Investor Relations - The company is Shanxi Jinbo Biological Pharmaceutical Co., Ltd., with stock code 832982 and abbreviation Jinbo Bio [1] - The investor relations activity was a telephone conference held on August 26, 2024, attended by various securities firms and investment funds [2][3] Group 2: Technology and Product Development - Jinbo Bio leads in recombinant humanized collagen technology, having solved four core issues: overcoming immunogenicity, achieving a precise triple helix structure, high activity (nearly 2 times that of human type III collagen), and enabling industrial-scale production [4][5] - The company has developed a self-crosslinking gel that does not use any crosslinking agents, enhancing support and longevity [5] Group 3: Clinical Progress and Market Position - The company has submitted a registration application for its mid-face volumizing gel product to the National Medical Products Administration, highlighting its competitive advantages over existing products [5][6] - In the functional skincare segment, the company achieved revenue of 47.98 million yuan in the first half of 2024, representing a year-on-year growth of 53.94% [8] Group 4: Strategic Partnerships and Growth - In the first half of 2024, the collaboration with L'Oréal deepened, with raw materials being used in both "Paris L'Oréal" and "SkinCeuticals" brands, contributing to increased revenue and brand influence [7] - The company plans to invest up to 220 million yuan in a production workshop for injectable recombinant humanized collagen, aiming to strengthen its leading position in the injection market [9]
锦波生物(832982) - 关于投资者关系活动记录表的公告